Pelvic Pain
Conditions
Interventions
This is a randomized, controlled, two-arm, parallel clinical trial involving 64 women with deep endometriosis and persistent pelvic pain. After the initial assessment, participants will be randomly al
however, therapists and participants will not be blinded. Both groups will receive an app-monitored home-based physiotherapy program combined with pain education for 8 weeks. Participants will be enco
Sponsors
Universidade do Estado de Santa Catarina
Maternidade Carmela Dutra
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women aged 18 to 45 years. Confirmed diagnosis of endometriosis. Having undergone surgery at least 3 months earlier, when applicable. Persistent pelvic pain for at least 3 months. Presence of pelvic floor muscle hypertonicity, myofascial pain syndrome, vulvodynia and/or pudendal nerve neuropathy. Access to audiovisual resources and internet
Exclusion criteria
Exclusion criteria: Women who are in menopause. Women undergoing fertility treatment or intending to start treatment within the next 3 months. Pregnant women. Women undergoing physiotherapeutic treatment or who have received physiotherapy within the last 3 months. Having sustained a lower limb fracture within the last 3 months that limits functional capacity. Cognitive disease that prevents the correct understanding of the exercises. Musculoskeletal pathology or neuropathy in the acute phase. Having had or currently having neoplastic disease. Untreated endometriosis. Acquired genital anomalies of the pelvis or pelvic floor. Women involved in litigation or financial compensation claims, or awaiting recognition of disability status. Severe mental illness, such as schizophrenia, borderline personality disorder, among others.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A reduction in pelvic pain intensity after the intervention is expected, assessed by algometry and a validated pain questionnaire, based on the comparison of the values and scores obtained at T1 (baseline), T2 (8 weeks), and T3 (16 weeks), with a reduction in pain symptoms and an increase in the pressure pain threshold compared with the baseline assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| An improvement in pelvic floor function is expected, assessed by bidigital palpation, electromyography, translabial ultrasound, myotonometry, and dynamometry, based on the comparison of the functional parameters obtained at T1, T2, and T3, with improvement in muscle contraction, functional performance, and muscle parameters compared with the baseline assessment.;An improvement in quality of life is expected, assessed by the Endometriosis Health Profile Questionnaire (EHP-30) and the Gastrointestinal Quality of Life Index (GIQLI), based on the comparison of the scores obtained at T1, T2, and T3, with score variation toward better quality of life according to the specific interpretation of each instrument, compared with the baseline assessment.;An improvement in sexual function is expected, assessed by the Female Sexual Function Index (FSFI), based on the comparison of the scores obtained at T1, T2, and T3, with score variation toward better sexual function according to the specific interpretation of the instrument, compared with the baseline assessment.;An improvement in mobility is expected, assessed by the Schober test, Motor Control test, and Sit-to-Stand test, based on the comparison of the performance obtained at T1, T2, and T3, with improvement in mobility and functionality compared with the baseline assessment.;An improvement in pain-related catastrophizing is expected, assessed by a validated instrument specific to catastrophizing, based on the comparison of the scores obtained at T1, T2, and T3, with score variation toward lower pain-related catastrophizing according to the specific interpretation of the instrument, compared with the baseline assessment.;An improvement in central sensitization is expected, assessed by the Central Sensitization Inventory (CSI), based on the comparison of the scores obtained at T1, T2, and T3, with score variation toward lower central sensitization according to the specific interpretation of the instrument, compared with the b | — |
Countries
BR, ES
Contacts
Public ContactClarissa Medeiros da Luz
Universidade do Estado de Santa Catarina
Outcome results
None listed